Base de dados : MEDLINE
Pesquisa : N03.540.514.718.800 [Categoria DeCS]
Referências encontradas : 30069 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3007 ir para página                         

  1 / 30069 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747142
[Au] Autor:Zhao Y; Stepto H; Schneider CK
[Ad] Endereço:1 Division of Advanced Therapies, National Institute for Biological Standards and Control (NIBSC) , Medicines and Health Products Regulatory Agency (MHRA), South Mimms, United Kingdom .
[Ti] Título:Development of the First World Health Organization Lentiviral Vector Standard: Toward the Production Control and Standardization of Lentivirus-Based Gene Therapy Products.
[So] Source:Hum Gene Ther Methods;28(4):205-214, 2017 08.
[Is] ISSN:1946-6544
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Gene therapy is a rapidly evolving field. So far, there have been >2,400 gene therapy products in clinical trials and four products on the market. A prerequisite for producing gene therapy products is ensuring their quality and safety. This requires appropriately controlled and standardized production and testing procedures that result in consistent safety and efficacy. Assuring the quality and safety of lentivirus-based gene therapy products in particular presents a great challenge because they are cell-based multigene products that include viral and therapeutic proteins as well as modified cells. In addition to the continuous refinement of a product, changes in production sites and manufacturing processes have become more and more common, posing challenges to developers regarding reproducibility and comparability of results. This paper discusses the concept of developing a first World Health Organization International Standard, suitable for the standardization of assays and enabling comparison of cross-trial and cross-manufacturing results for this important vector platform. The standard will be expected to optimize the development of gene therapy medicinal products, which is especially important, given the usually orphan nature of the diseases to be treated, naturally hampering reproducibility and comparability of results.
[Mh] Termos MeSH primário: Terapia Genética/normas
Vetores Genéticos/normas
Lentivirus/genética
Organização Mundial da Saúde
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Terapia Genética/métodos
Vetores Genéticos/genética
Células HEK293
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180310
[Lr] Data última revisão:
180310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1089/hgtb.2017.078


  2 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28455172
[Au] Autor:Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
[Ad] Endereço:Department of Pediatrics, Universidad del Valle and Centro de Estudios en Infectología Pediátrica, Cali, Colombia.
[Ti] Título:Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
[So] Source:Vaccine;35(28):3591-3597, 2017 06 16.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufacturers. METHODS: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study groups received three doses of bOPV at 6, 10 and 14weeks and either one IPV dose at 14weeks (groups SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36weeks (groups SP-2, GSK-2 and BBio-2) from three different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40weeks (two IPV doses) and stools were collected weekly for 4weeks to assess viral shedding. Serum neutralizing antibodies were measured at various time points pre and post vaccination. Serious adverse events and important medical events (SAE and IME) were monitored for 6months after last study vaccine. RESULTS: At week 18, 4weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4% and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were seronegative before IPV administration. At 40weeks, 4weeks after a second IPV dose, type 2 seroconversion rates were ≥99% for any of the three manufacturers. There were no significant differences in fecal shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1-2.6]); GSK: 2.2 [1.7-2.5]; BBio 1.8 [1.5-2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME. CONCLUSION: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal immunity after one or two doses. The parent study was registered with ClinicalTrials.gov, number NCT01831050.
[Mh] Termos MeSH primário: Esquemas de Imunização
Imunogenicidade da Vacina
Vacina Antipólio de Vírus Inativado/efeitos adversos
Vacina Antipólio de Vírus Inativado/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/sangue
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Fezes/virologia
Feminino
Seres Humanos
Imunidade Humoral
Lactente
Intestinos/imunologia
América Latina
Masculino
Poliomielite/prevenção & controle
Vacina Antipólio de Vírus Inativado/administração & dosagem
Vacina Antipólio Oral/administração & dosagem
Vacina Antipólio Oral/efeitos adversos
Vacina Antipólio Oral/imunologia
Soroconversão
Vacinação
Eliminação de Partículas Virais
Organização Mundial da Saúde
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Poliovirus Vaccine, Inactivated); 0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  3 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232052
[Au] Autor:Chahal HS; Murray JS; Shimer M; Capella P; Presto R; Valdez ML; Lurie PG
[Ad] Endereço:Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD.
[Ti] Título:The US Food and Drug Administration's tentative approval process and the global fight against HIV.
[So] Source:J Int AIDS Soc;20(4), 2017 Dec.
[Is] ISSN:1758-2652
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In 2004, the US government began to utilize the Food and Drug Administration's (USFDA) tentative approval process (tFDA) as a basis to determine which HIV drugs are appropriate to be purchased and used in resource-constrained settings. This process permits products that are not approved for marketing in the US, including medicines with active patents or marketing restrictions in the US, to be purchased and distributed in resource-constrained settings. Although the tFDA was originally intended to support the United States' President's Emergency Plan for AIDS Relief (PEPFAR), the USFDA list has become a cornerstone of international HIV programmes that support procurement of ARVs, such as the World Health Organization and the Global Fund to Fight AIDS, Tuberculosis, and Malaria. Our objective in this article is to help the global HIV policy makers and implementers of HIV programmes better understand the benefits and limitations of the tFDA by providing an in-depth review of the relevant legal and regulatory processes. DISCUSSION: USFDA's dedicated tFDA process for ARVs used by the PEPFAR programme has a wide impact globally; however, the implementation and the regulatory processes governing the programme have not been thoroughly described in the medical literature. This paper seeks to help stakeholders better understand the legal and regulatory aspects associated with review of ARVs under the tFDA by describing the following: (1) the tFDA and its importance to global ARV procurement; (2) the regulatory pathways for applications under tFDA for the PEPFAR programme, including modifications to applications, review timelines and costs; (3) the role of US patents, US marketing exclusivity rights, and the Medicines Patents Pool in tFDA; and (4) an overview of how applications for PEPFAR programme are processed through the USFDA. We also provide a case study of a new ARV, tenofovir alafenamide fumarate (TAF), not yet reviewed by USFDA for PEPFAR use. CONCLUSIONS: In this paper, we describe the importance and implementation of USFDA's tentative approval process to review ARVs for resource-constrained settings. We also highlight the impact of patents and exclusivities on review of HIV drugs under tFDA and illustrate the concepts using a new HIV drug as an example.
[Mh] Termos MeSH primário: Fármacos Anti-HIV
Aprovação de Drogas
Infecções por HIV/tratamento farmacológico
[Mh] Termos MeSH secundário: Saúde Global
Seres Humanos
Cooperação Internacional
Tuberculose
Estados Unidos
United States Food and Drug Administration
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1002/jia2.25019


  4 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29330159
[Au] Autor:Whitaker K; Webb D; Linou N
[Ad] Endereço:HIV, Health, and Development Group, Bureau for Policy and Programme Support, UNDP, New York, NY, USA.
[Ti] Título:Commercial influence in control of non-communicable diseases.
[So] Source:BMJ;360:k110, 2018 01 12.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Controle de Doenças Transmissíveis/economia
Indústrias/normas
Doenças não Transmissíveis/epidemiologia
Médicos/psicologia
[Mh] Termos MeSH secundário: Controle de Doenças Transmissíveis/normas
Saúde Global/economia
Saúde Global/legislação & jurisprudência
Política de Saúde/economia
Política de Saúde/legislação & jurisprudência
Seres Humanos
Indústrias/organização & administração
Mortalidade Prematura
Doenças não Transmissíveis/mortalidade
Médicos/ética
Formulação de Políticas
Fatores de Risco
Organização Mundial da Saúde/organização & administração
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180114
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k110


  5 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28423994
[Au] Autor:Schüttoff U; Pawlowski T
[Ad] Endereço:a Faculty of Economics and Social Science, Institute of Sports Science , University of Tübingen , Tübingen , Germany.
[Ti] Título:Seasonal variation in sports participation.
[So] Source:J Sports Sci;36(4):469-475, 2018 Feb.
[Is] ISSN:1466-447X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study explores indicators describing socio-demographics, sports participation characteristics and motives which are associated with variation in sports participation across seasons. Data were drawn from the German Socio-Economic Panel which contains detailed information on the sports behaviour of adults in Germany. Overall, two different measures of seasonal variation are developed and used as dependent variables in our regression models. The first variable measures the coefficient of (seasonal) variation in sport-related energy expenditure per week. The second variable measures whether activity drops below the threshold as defined by the World Health Organization (WHO). Results suggest that the organisational setting, the intensity and number of sports practised, and the motive for participation are strongly correlated with the variation measures used. For example, both, participation in a sports club and a commercial facility, are associated with reduced seasonal variation and a significantly higher probability of participating at a volume above the WHO threshold across all seasons. These findings give some impetus for policymaking and the planning of sports programmes as well as future research directions.
[Mh] Termos MeSH primário: Motivação
Estações do Ano
Esportes/psicologia
[Mh] Termos MeSH secundário: Adulto
Metabolismo Energético
Feminino
Alemanha
Guias como Assunto
Comportamentos Relacionados com a Saúde
Seres Humanos
Masculino
Análise de Regressão
Fatores Socioeconômicos
Esportes/fisiologia
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1080/02640414.2017.1316864


  6 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29474026
[Ti] Título:BCG vaccines: WHO position paper ­ February 2018.
[Ti] Título:Vaccins BCG: Note de synthèse de l'OMS ­ Février 2018..
[So] Source:Wkly Epidemiol Rec;93(8):73-96, 2018 Feb 23.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Vacina BCG/administração & dosagem
Guias como Assunto/normas
Programas de Imunização/normas
Organização Mundial da Saúde
[Mh] Termos MeSH secundário: Adulto
Comitês Consultivos/normas
Idoso
Úlcera de Buruli/diagnóstico
Úlcera de Buruli/epidemiologia
Úlcera de Buruli/terapia
Criança
Pré-Escolar
Feminino
Saúde Global/estatística & dados numéricos
Seres Humanos
Programas de Imunização/estatística & dados numéricos
Esquemas de Imunização
Imunização Secundária
Lactente
Hanseníase/diagnóstico
Hanseníase/epidemiologia
Hanseníase/terapia
Masculino
Meia-Idade
Gravidez
Tuberculose/diagnóstico
Tuberculose/epidemiologia
Tuberculose/terapia
Tuberculose/transmissão
Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia
Tuberculose Pulmonar/diagnóstico
Tuberculose Pulmonar/epidemiologia
Tuberculose Pulmonar/terapia
Tuberculose Pulmonar/transmissão
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (BCG Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180224
[St] Status:MEDLINE


  7 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450436
[Au] Autor:Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
[Ad] Endereço:From the Department of Radiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, P.R. China.
[Ti] Título:Noninvasive Assessment of Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.
[So] Source:AJNR Am J Neuroradiol;38(6):1138-1144, 2017 Jun.
[Is] ISSN:1936-959X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: ( ) has been shown to have both diagnostic and prognostic implications in gliomas. The purpose of this study was to examine whether DWI and DSC-PWI combined with conventional MR imaging could noninvasively predict mutational status in World Health Organization grade II and III astrocytomas. MATERIALS AND METHODS: We retrospectively reviewed DWI, DSC-PWI, and conventional MR imaging in 42 patients with World Health Organization grade II and III astrocytomas. Minimum ADC, relative ADC, and relative maximum CBV values were compared between -mutant and wild-type tumors by using the Mann-Whitney test. Receiver operating characteristic curve and logistic regression were used to assess their diagnostic performances. RESULTS: Minimum ADC and relative ADC were significantly higher in -mutated grade II and III astrocytomas than in wild-type tumors ( < .05). Minimum ADC with the cutoff value of ≥1.01 × 10 mm /s could differentiate the mutational status with a sensitivity, specificity, positive predictive value, and negative predictive value of 76.9%, 82.6%, 91.2%, and 60.5%, respectively. The threshold value of <2.35 for relative maximum CBV in the prediction of mutation provided a sensitivity, specificity, positive predictive value, and negative predictive value of 100.0%, 60.9%, 85.6%, and 100.0%, respectively. A combination of DWI, DSC-PWI, and conventional MR imaging for the identification of mutations resulted in a sensitivity, specificity, positive predictive value, and negative predictive value of 92.3%, 91.3%, 96.1%, and 83.6%. CONCLUSIONS: A combination of conventional MR imaging, DWI, and DSC-PWI techniques produces a high sensitivity, specificity, positive predictive value, and negative predictive value for predicting mutations in grade II and III astrocytomas. The strategy of using advanced, semiquantitative MR imaging techniques may provide an important, noninvasive, surrogate marker that should be studied further in larger, prospective trials.
[Mh] Termos MeSH primário: Astrocitoma/diagnóstico por imagem
Neoplasias Encefálicas/diagnóstico por imagem
Análise Mutacional de DNA/métodos
Isocitrato Desidrogenase/genética
Imagem por Ressonância Magnética/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Astrocitoma/genética
Astrocitoma/patologia
Neoplasias Encefálicas/genética
Neoplasias Encefálicas/patologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Mutação
Estudos Prospectivos
Curva ROC
Estudos Retrospectivos
Sensibilidade e Especificidade
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 1.1.1.41 (Isocitrate Dehydrogenase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.3174/ajnr.A5171


  8 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241618
[Au] Autor:Agweyu A; Lilford RJ; English M; Clinical Information Network Author Group
[Ad] Endereço:Health Services Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya; Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: aagweyu@kemri-wellcome.org.
[Ti] Título:Appropriateness of clinical severity classification of new WHO childhood pneumonia guidance: a multi-hospital, retrospective, cohort study.
[So] Source:Lancet Glob Health;6(1):e74-e83, 2018 Jan.
[Is] ISSN:2214-109X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Management of pneumonia in many low-income and middle-income countries is based on WHO guidelines that classify children according to clinical signs that define thresholds of risk. We aimed to establish whether some children categorised as eligible for outpatient treatment might have a risk of death warranting their treatment in hospital. METHODS: We did a retrospective cohort study of children aged 2-59 months admitted to one of 14 hospitals in Kenya with pneumonia between March 1, 2014, and Feb 29, 2016, before revised WHO pneumonia guidelines were adopted in the country. We modelled associations with inpatient mortality using logistic regression and calculated absolute risks of mortality for presenting clinical features among children who would, as part of revised WHO pneumonia guidelines, be eligible for outpatient treatment (non-severe pneumonia). FINDINGS: We assessed 16 162 children who were admitted to hospital in this period. 832 (5%) of 16 031 children died. Among groups defined according to new WHO guidelines, 321 (3%) of 11 788 patients with non-severe pneumonia died compared with 488 (14%) of 3434 patients with severe pneumonia. Three characteristics were strongly associated with death of children retrospectively classified as having non-severe pneumonia: severe pallor (adjusted risk ratio 5·9, 95% CI 5·1-6·8), mild to moderate pallor (3·4, 3·0-3·8), and weight-for-age Z score (WAZ) less than -3 SD (3·8, 3·4-4·3). Additional factors that were independently associated with death were: WAZ less than -2 to -3 SD, age younger than 12 months, lower chest wall indrawing, respiratory rate of 70 breaths per min or more, female sex, admission to hospital in a malaria endemic region, moderate dehydration, and an axillary temperature of 39°C or more. INTERPRETATION: In settings of high mortality, WAZ less than -3 SD or any degree of pallor among children with non-severe pneumonia was associated with a clinically important risk of death. Our data suggest that admission to hospital should not be denied to children with these signs and we urge clinicians to consider these risk factors in addition to WHO criteria in their decision making. FUNDING: Wellcome Trust.
[Mh] Termos MeSH primário: Pneumonia/classificação
Pneumonia/terapia
Guias de Prática Clínica como Assunto
Índice de Gravidade de Doença
[Mh] Termos MeSH secundário: Assistência Ambulatorial
Pré-Escolar
Feminino
Hospitalização
Seres Humanos
Lactente
Quênia/epidemiologia
Masculino
Pneumonia/mortalidade
Estudos Retrospectivos
Medição de Risco/métodos
Resultado do Tratamento
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  9 / 30069 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29450989
[Ti] Título:Implementation of hepatitis B birth dose vaccination ­ worldwide, 2016.
[Ti] Título:Mise en oeuvre de la vaccination contre l'hépatite B par une dose à la naissance à l'échelle mondiale, 2016..
[So] Source:Wkly Epidemiol Rec;93(7):61-72, 2018 Feb 16.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Vacinas contra Hepatite B/administração & dosagem
Hepatite B/prevenção & controle
Hepatite B/transmissão
Esquemas de Imunização
Transmissão Vertical de Doença Infecciosa/prevenção & controle
[Mh] Termos MeSH secundário: Saúde Global
Seres Humanos
Recém-Nascido
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180217
[St] Status:MEDLINE


  10 / 30069 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Colômbia
Texto completo SciELO Saúde Pública
[PMID]:28453057
[Au] Autor:Benjumea-Rincón MV; Parra-Sánchez JH; Ocampo-Téllez PR
[Ad] Endereço:Universidad de Caldas, Manizales, Colombia.
[Ti] Título:[Correlation of size and age in Colombian indigenous children based on WHO and NCHS references].
[Ti] Título:Concordancia en la talla para la edad entre referencias NCHS y OMS en indígenas colombianos..
[So] Source:Rev Salud Publica (Bogota);18(4):503-515, 2016 Aug.
[Is] ISSN:0124-0064
[Cp] País de publicação:Colombia
[La] Idioma:spa
[Ab] Resumo:Objective To evaluate the correlation of size, according to age, of the anthropometric growth references of Colombian indigenous children studied in Encuesta Nacional de la Situación Nutricional de Colombia 2010 -ENSIN 2010 (National Survey of Nutrition in Colombia - 2010). Method A secondary analysis of 2598 data of indigenous Colombian children under five years of age, evaluated by ENSIN in 2010, was performed. The considered variables were size according to age, gender, height, place of residence, department and socioeconomic position. The classification of the deficit in size, based on the references of the National Center for Health Statistics (NCHS) and the World Health Organization (WHO), was made by using the Z <-2 score and the Anthro software. The Kappa coefficient was estimated to assess the correlation between anthropometric categories and was classified taking into account the proposal of Altman DG. Results One in four children had a deficit in size in the light of both anthropometric references. The prevalence of the deficit was higher when using the WHO standard, increased with age and was higher in children who resided in low altitude (m). The correlation between the two references was good (kappa ≥0,688, p=0,000) for children of both genders and all ages; the exception corresponded to children of age two, since it was moderate (kappa=0,601, p=0,000). The greatest disagreement in the classification was observed in the category "tall". Conclusion According to the statistical correlation found between the two anthropometric references (WHO vs. NCHS), any reference could be used for assessment of size according to for age.
[Mh] Termos MeSH primário: Fatores Etários
Estatura/etnologia
Índios Sul-Americanos
[Mh] Termos MeSH secundário: Pré-Escolar
Colômbia
Estudos Transversais
Feminino
Seres Humanos
Lactente
Recém-Nascido
Masculino
National Center for Health Statistics (U.S.)
Estado Nutricional
Valores de Referência
Reprodutibilidade dos Testes
Estudos Retrospectivos
Fatores Sexuais
Estados Unidos
Organização Mundial da Saúde
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE



página 1 de 3007 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde